VXRT240719C5000
- 0.05
- 0.000.00%
Vaxart Newsroom
Individual Investors Who Own 59% Along With Institutions Invested in Vaxart, Inc. (NASDAQ:VXRT) Saw Increase in Their Holdings Value Last Week
Key Insights Significant control over Vaxart by individual investors implies that the general public has more power to influence management and governance-related decisions 22% of the business is he
While Institutions Invested in Vaxart, Inc. (NASDAQ:VXRT) Benefited From Last Week's 23% Gain, Retail Investors Stood to Gain the Most
Vaxart(VXRT.US) Director Buys US$13,578 in Common Stock
$Vaxart(VXRT.US)$ Director Watson W. Mark purchased 20,000 shares of common stock on Jun 18, 2024 at an average price of $0.6789 for a total value of $13,578.Source: Announcement What is statement of
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersGeovax Labs (NASDAQ:GOVX) stock moved upwards by 72.1% to $1.91 during Wednesday's regular session. The company's market cap stands at $4.8 million. Nexalin Technology (NASDAQ:NXL) shares incre
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersMustang Bio (NASDAQ:MBIO) stock moved upwards by 50.0% to $1.12 during Tuesday's regular session. The company's market cap stands at $31.7 million. Sonoma Pharmaceuticals (NASDAQ:SNOA) shares i
Vaxart Shares Are Trading Higher After the Company Announced Its Business and Cash Runaway Updates.
Vaxart Shares Are Trading Higher After the Company Announced Its Business and Cash Runaway Updates.
Vaxart Anticipates Funds to Extend Its Cash Runway Into 2026
Vaxart Stock Is Moving Higher After The Bell: What's Going On?
Vaxart Inc (NASDAQ:VXRT) shares are trading higher in Monday's after-hours session after the company provided business and cash runway updates.
Vaxart Provides Business Update; Expects Net Proceeds From $40M Offering And Reimbursment Under Project NextGen Award Of Up To $453M To Extend Cash Runaway Into 2026
— Cash runway extended into 2026 —— Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million —— Company well-capitalized to execute on multiple key clinical and regu
Express News | Vaxart Inc: Well-Capitalized to Execute on Multiple Key Clinical and Regulatory Milestones in Covid-19 and Norovirus Programs
Express News | Vaxart Inc: Received One of Largest Barda-Funded Project Nextgen Awards to Date, up to $453 Mln
Express News | Vaxart Inc: Cash Runway Extended Into 2026
Vaxart Provides Business Update
Vaxart, Inc. (Nasdaq: VXRT) today provided business and cash runway updates as the Company continues to advance its oral pill vaccine platform.
Warning! US experts are concerned that if the bird flu virus mutates and evolves, a pandemic may occur.
This round of bird flu transmission has the characteristic of wide spread and extremely strong infectivity. At present, apart from Australia, relevant cases have been reported in other continents around the world. In addition to livestock, there have been several cases of human infection with avian flu virus this year, which has greatly alarmed the academic community. Former director of the US Centers for Disease Control and Prevention warned that humans may face a pandemic of bird flu.
Vaxart Shares Are Trading Lower After the Company Launched a $40 Million Underwritten Offering of 50 Million Shares at $0.80 per Share.
Vaxart Shares Are Trading Lower After the Company Launched a $40 Million Underwritten Offering of 50 Million Shares at $0.80 per Share.
Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering
Vaxart, Inc. (NASDAQ:VXRT) shares traded higher in the premarket session on Friday, up more than 23% at one point.Vaxart's average session volume was about 1.6 million. Friday premarket's session volu
Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday
Health care stocks were leaning lower pre-bell Friday with the Health Care Select Sector SPDR Fund (XLV) and iShares Biotechnology ETF (IBB) recently declining by 0.3% Cabaletta Bio (CABA) was over 4%
B.Riley Financial Maintains Vaxart(VXRT.US) With Buy Rating, Raises Target Price to $2.5
B.Riley Financial analyst Mayank Mamtani maintains $Vaxart(VXRT.US)$ with a buy rating, and adjusts the target price from $2 to $2.5.According to TipRanks data, the analyst has a success rate of 25.4%
Why Adobe Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Shares of Adobe Inc. (NASDAQ:ADBE) rose sharply in today's pre-market trading following better-than-expected second-quarter earnings and strong guidance.Adobe reported second-quarter revenue of $5.31
B. Riley Raises Price Target on Vaxart to $2.50 From $2, Maintains Buy Rating
B. Riley Raises Price Target on Vaxart to $2.50 From $2, Maintains Buy Rating.